Brooklyn ImmunoTherapeutics Inc. (BTX) stock had a negative Thursday, April 29, 2021. In the normal trading session, BTX lost 21.75% to close at $34.22 per share. the slump continued in the after-hours session and it further lost 8.39% to close at $31.35 per share.
BTX shares have soared 1413.76% over the last 12 months, and they have moved up by 174.20% in the past week. Over the past three months, the stock has surged 317.32%, while over the past six months, it has rocketed 714.76%.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Let’s see why BTX stock had a bad Thursday?
Exclusive License acquisition for the mRNA technology platform
On April 29, 2021, Brooklyn ImmunoTherapeutics said that it has acquired an exclusive license for mRNA gene editing and cell therapies technology.
The license will also provide to use an extensively patented process to develop gene-editing compounds using mRNA, which preclinical data suggest demonstrating a high degree of efficiency, as well as being non-immunogenic and non-mutagenic.
On April 26, 2021, Brooklyn ImmunoTherapeutics appointed Matthew During, M.D., Ph.D. to the Company’s Scientific Advisory Board, effective immediately.
Dr. During is a Harvard, MIT, and Yale-trained neuroscientist with vast working experience as a faculty member at different reputable universities.
On April 19, 2021, Brooklyn ImmunoTherapeutics reported that the company granted a nonqualified stock option covering 2,627,915 shares of Brooklyn’s common stock to Dr. Federof.
Previously on 16 April 2021, Dr. Federoff was granted a nonqualified stock option covering 597,253 shares of Brooklyn’s common stock. This inducement grant is given to Dr. Federoff’s for his devoted continuous service with Brooklyn.
mRNA Technology Platform license Acquisition
On April 15, 2021, Brooklyn ImmunoTherapeutics paid $1 million to acquire the Factor Bioscience’s and Novellus’ mRNA Gene Editing and Cell Therapies technology license which has been extended till May 21, 2021.
Upon completion, Brooklyn would be able to start a patented process to seek to develop gene-edited compounds using mRNA which are used for the treatment of several solid tumour and liquid indications, sickle cell anemia, as well as for several additional inherited disorders.
New Board member
On April 15, 2021, Brooklyn ImmunoTherapeutics appointed Dennis H. Langer, M.D., J.D. to the Company’s Board as an Independent Director, effective May 1, 2021.
New CEO appointment
On April 6, 2021, Brooklyn ImmunoTherapeutics appointed Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and President and a director as of 16 April 2021.
Ronald Guido was replaced by Dr. Federoff, who was serving as Interim CEO and will remain on Brooklyn’s management team as Chief Development Officer.
Well, BTX negative performance on Thursday is strange because there is no such news. There is positive news and it still faced negativity in the market. We are pretty confident it to bounce back on Friday, based on its exceptional past performance.